These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31255354)

  • 1. Impact of CYP3A5 Genetic Polymorphism on Intrapatient Variability of Tacrolimus Exposure in Chinese Kidney Transplant Recipients.
    Cheung CY; Chan KM; Wong YT; Chak WL; Bekers O; van Hooff JP
    Transplant Proc; 2019; 51(6):1754-1757. PubMed ID: 31255354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of CYP3A5 Genetic Polymorphism on Long-Term Renal Function in Chinese Kidney Transplant Recipients Using Limited Sampling Strategy and Abbreviated Area Under the Curve for Tacrolimus Monitoring.
    Cheung CY; Chan KM; Wong YT; Chak WL; Bekers O; van Hooff JP
    Prog Transplant; 2020 Sep; 30(3):249-253. PubMed ID: 32552577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP3A5 genotype had no impact on intrapatient variability of tacrolimus clearance in renal transplant recipients.
    Spierings N; Holt DW; MacPhee IA
    Ther Drug Monit; 2013 Jun; 35(3):328-31. PubMed ID: 23666583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients.
    Miura M; Satoh S; Kagaya H; Saito M; Numakura K; Tsuchiya N; Habuchi T
    Pharmacogenomics; 2011 Jul; 12(7):977-84. PubMed ID: 21635144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation.
    Yaowakulpatana K; Vadcharavivad S; Ingsathit A; Areepium N; Kantachuvesiri S; Phakdeekitcharoen B; Sukasem C; Sra-Ium S; Sumethkul V; Kitiyakara C
    Eur J Clin Pharmacol; 2016 Mar; 72(3):277-83. PubMed ID: 26635230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.
    Trofe-Clark J; Brennan DC; West-Thielke P; Milone MC; Lim MA; Neubauer R; Nigro V; Bloom RD
    Am J Kidney Dis; 2018 Mar; 71(3):315-326. PubMed ID: 29162334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
    Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
    S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing.
    García-Roca P; Medeiros M; Reyes H; Rodríguez-Espino BA; Alberú J; Ortiz L; Vásquez-Perdomo M; Elizondo G; Morales-Buenrostro LE; Mancilla Urrea E; Castañeda-Hernández G
    Arch Med Res; 2012 May; 43(4):283-7. PubMed ID: 22704849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of CYP3A5 genomic variances on clinical outcomes among African American kidney transplant recipients.
    Asempa TE; Rebellato LM; Hudson S; Briley K; Maldonado AQ
    Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29161757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Voriconazole in Chinese Kidney Transplant Patients.
    Zhang Y; Du Y; Ren S; Li Y; Zhang X; Cao X; Liu F; Zong H; Li Y
    Ann Pharmacother; 2024 Jun; 58(6):605-613. PubMed ID: 37702380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Tacrolimus Intra-Patient Variability during 6-12 Months after Kidney Transplantation between CYP3A5 Expressers and Nonexpressers.
    Nuchjumroon A; Vadcharavivad S; Singhan W; Poosoonthornsri M; Chancharoenthana W; Udomkarnjananun S; Townamchai N; Avihingsanon Y; Praditpornsilpa K; Eiam-Ong S
    J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients.
    Yanik MV; Seifert ME; Locke JE; Hauptfeld-Dolejsek V; Crowley MR; Cutter GR; Mannon RB; Feig DI; Limdi NA
    Pediatr Transplant; 2019 Aug; 23(5):e13494. PubMed ID: 31124575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of De Novo Donor-specific HLA Antibodies and AMR in Renal Transplant Patients Depends on CYP3A5 Genotype.
    Friebus-Kardash J; Nela E; Möhlendick B; Kribben A; Siffert W; Heinemann FM; Eisenberger U
    Transplantation; 2022 May; 106(5):1031-1042. PubMed ID: 34241984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation.
    Ro H; Min SI; Yang J; Moon KC; Kim YS; Kim SJ; Ahn C; Ha J
    Ther Drug Monit; 2012 Dec; 34(6):680-5. PubMed ID: 23149441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Effect of Inter- and Intrapatient Variability in Tacrolimus Exposure on Graft Impairment Within a 3-Year Period Following Kidney Transplantation: A Single-Center Experience.
    Stefanović NZ; Veličković-Radovanović RM; Danković KS; Mitić BP; Paunović GJ; Cvetković MB; Cvetković TP
    Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):749-760. PubMed ID: 32886348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers.
    Tang HL; Xie HG; Yao Y; Hu YF
    Pharmacogenet Genomics; 2011 Nov; 21(11):713-20. PubMed ID: 21886016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between CYP3A5 Genetic Polymorphisms with Tacrolimus Dose Requirement and Allograft Outcomes in Iranian Kidney Transplant Recipients.
    Ghafari S; Dashti-Khavidaki S; Khatami MR; Ghahremani MH; Seyednejad SA; Beh-Pajooh A
    Iran J Kidney Dis; 2019 Nov; 13(6):414-416. PubMed ID: 31880588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P450 oxidoreductase *28 (POR*28) and tacrolimus disposition in pediatric kidney transplant recipients--a pilot study.
    Gijsen VM; van Schaik RH; Soldin OP; Soldin SJ; Nulman I; Koren G; de Wildt SN
    Ther Drug Monit; 2014 Apr; 36(2):152-8. PubMed ID: 24089076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.